IRCCS Ospedale Auxologico San Luca

At IRCCS Ospedale Auxologico San Luca in Milan, research in cardiovascular diseases focuses on improving treatment strategies for conditions such as coronary syndromes, atrial fibrillation, heart failure, hypertension, and hypertrophic cardiomyopathy. These studies are designed to test new therapies, refine antithrombotic care, and better control blood pressure and cardiac symptoms.

• Coronary disease and atrial fibrillation research is examining safer antithrombotic approaches after PCI.
• Hypertension studies are evaluating novel options for resistant and uncontrolled blood pressure.
• Heart failure and hypertrophic cardiomyopathy trials are assessing ways to improve function and symptoms.

Overall, the site contributes to clinical research aimed at reducing cardiovascular risk while improving day-to-day outcomes for patients with complex heart disease.

Clinical trials at this site also cover a broad range of endocrine and metabolic disorders, including thyroid eye disease, Graves’ disease, congenital adrenal hyperplasia, Cushing syndrome, and primary aldosteronism. The main goal is to evaluate new treatments that may help regulate hormones, reduce symptoms, and improve disease control.

• Thyroid-related diseases are being studied to improve eye and hormone outcomes.
• Adrenal disorders research is focused on lowering steroid burden and controlling excess hormone production.
• Metabolic conditions such as overweight and obesity are included in trials that also address joint pain.

These studies reflect a strong interest in therapies that target the underlying biology of hormone-related illness rather than only the symptoms.

The site supports active research in neurology and psychiatry, with trials in amyotrophic lateral sclerosis, migraine, Parkinson’s disease, cervical dystonia, frontotemporal dementia, and Alzheimer’s disease-related agitation and psychosis. These studies aim to test potential new treatments, slow disease progression, and improve symptom control and quality of life.

• ALS studies are evaluating therapies for slowing functional decline.
• Migraine trials are focused on both acute relief and prevention.
• Dementia-related behavioral symptoms are being studied to better manage agitation and psychosis.

This mix of trials shows a broad commitment to both neurodegenerative disease research and treatment options for disabling neurological symptoms.

Research in immune-mediated disease includes studies of eosinophilic granulomatosis with polyangiitis and other inflammatory conditions, with a focus on improving remission rates and disease control. These trials are designed to assess whether newer therapies can better manage inflammation and reduce flare-ups.

• EGPA studies are examining remission maintenance and safety.
• Inflammatory disease research is centered on controlling immune activity more effectively.
• Respiratory and systemic inflammation are part of the broader therapeutic scope at the site.

By exploring targeted immune therapies, the site contributes to research that may offer more durable control for patients with complex inflammatory disease.

The clinical trial portfolio also includes studies in musculoskeletal and pelvic pain conditions, such as knee osteoarthritis and chronic pelvic pain syndrome. These trials aim to reduce pain, improve function, and explore better symptom management strategies.

• Knee osteoarthritis studies are looking at weight and pain improvement.
• Chronic pelvic pain syndrome research is testing approaches to relieve persistent discomfort.
• Physiological outcomes are being used to understand how treatment may affect daily well-being.

Although smaller in number, these trials broaden the site’s research profile beyond cardiovascular and neurological care.